---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284805734.md"
description: "NewcelX shares are trading higher after the company reported a year-over-year increase in FY EPS results. The company announced it expects to expand development collaborations for Diabetes drugs in 2026."
datetime: "2026-04-30T15:55:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284805734.md)
  - [en](https://longbridge.com/en/news/284805734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284805734.md)
---

# 

NewcelX shares are trading higher after the company reported a year-over-year increase in FY EPS results. The company announced it expects to expand development collaborations for Diabetes drugs in 2026.

### Related Stocks

- [NCEL.US](https://longbridge.com/en/quote/NCEL.US.md)
- [NLSPW.US](https://longbridge.com/en/quote/NLSPW.US.md)

## Related News & Research

- [EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug](https://longbridge.com/en/news/284765384.md)
- [BUZZ-NewcelX rises after raising funds at premium to boost diabetes program](https://longbridge.com/en/news/281358909.md)
- [NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing | NCEL Stock News](https://longbridge.com/en/news/281357100.md)
- [NewcelX Strengthens IP Portfolio with Chinese Patent Publication](https://longbridge.com/en/news/269402766.md)
- [NewcelX and Eledon partner for NCEL-101 programme](https://longbridge.com/en/news/278530365.md)